The impact of low-dose aspirin on adverse perinatal outcomes: a meta-analysis and meta-regression.
Low-dose aspirin has been shown to reduce the risk of pre-eclampsia, low birthweight and preterm birth whilst its effect on adverse perinatal outcomes (including 5-minute Apgar score <7, neonatal intensive care unit admission, acidosis, periventricular haemorrhage and perinatal death) remains unclear. To perform a meta-analysis and meta-regression of randomised controlled trials to evaluate the impact of low dose aspirin on perinatal outcomes independent of its effect on pre-eclampsia, preterm birth and low birthweight. We searched Embase, Pubmed, CENTRAL and Google Scholar identifying randomised controlled trials, that analysed the impact of low dose aspirin in pregnancy, published in English prior to May 2019 which reported perinatal outcomes of interest (placental abruption, mode of birth, low 5-minute Apgar score, neonatal acidosis, neonatal intensive care unit admission, periventricular haemorrhage and perinatal death). Risk ratios and 95% confidence intervals were calculated and pooled for analysis. Analysis was stratified according to gestation at commencement of treatment - ≤16 weeks or >16 weeks and meta-regression was used to assess the impact on outcomes independent of the reduction in pre-eclampsia, preterm birth and low birthweight. Forty studies containing 34,807 participants were included. When low dose aspirin was commenced <16 weeks gestation it was associated with a significant reduction in the risk of perinatal death (RR 0.47, 95%CI 0.25-0.88, p=0.02; Number Needed to Treat = 92). If commenced >16 weeks gestation there was a significant reduction in 5-minute Apgar score<7 (RR 0.75 95%CI 0.58-0.96, p=0.02) and periventricular haemorrhage (RR 0.68, 95%CI 0.47-0.99, p=0.04) but a trend towards an increase in the risk of placental abruption (RR 1.20, 95% CI 1.00-1.46, p=0.06). LDA was not associated with any significant increase in adverse events if commenced <16 weeks gestation. Low dose aspirin had no effect on mode of birth. Meta-regression confirmed that the effect of low dose aspirin on perinatal death when treatment was started <16 weeks gestation was independent of any reduction in rates of pre-eclampsia and preterm birth. Low dose aspirin improves some important perinatal outcomes without increasing adverse events such as placental abruption or periventricular haemorrhage and its utility if commenced prior to 16 weeks gestation may be considered in a wider context beyond the prevention of pre-eclampsia or fetal growth restriction. This article is protected by copyright. All rights reserved.